SkinBioTherapeutics (LON:SBTX) Posts Quarterly Earnings Results

SkinBioTherapeutics (LON:SBTX) announced its quarterly earnings data on Wednesday. The company reported GBX (0.46) (($0.01)) earnings per share (EPS) for the quarter, Digital Look Earnings reports. SkinBioTherapeutics had a negative net margin of 237.95% and a negative return on equity of 115.86%.

SkinBioTherapeutics Price Performance

Shares of SBTX traded up GBX 0.23 ($0.00) during midday trading on Wednesday, hitting GBX 23.48 ($0.30). The company’s stock had a trading volume of 1,891,064 shares, compared to its average volume of 808,888. The company has a quick ratio of 10.01, a current ratio of 0.93 and a debt-to-equity ratio of 27.57. SkinBioTherapeutics has a one year low of GBX 8.32 ($0.11) and a one year high of GBX 26.45 ($0.34). The stock has a market capitalization of £53.63 million, a price-to-earnings ratio of -14.44 and a beta of 2.01. The company’s fifty day simple moving average is GBX 19.67 and its two-hundred day simple moving average is GBX 16.46.

SkinBioTherapeutics Company Profile

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.